Surprisingly, no significant difference was identified between the “CDH1-altered” and “CDH1-unaltered” ILC groups in any of the demographics or clinical or pathological characteristics, including tumor size, histologic grade, lymph node metastasis, stage, or hormonal receptor (ER/PR/HER2) states (Table 1). The gene discussed is ESR1; the disease is metastatic malignant neoplasm in the lymph nodes.